These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36175924)

  • 1. Treatment persistence with aripiprazole once monthly: a 4-year follow-up.
    Fagiolini A; Aguglia E; Ballerini A; Callista G; Carpiniello B; Clerici M; Corrivetti G; Cuomo A; De Fazio P; De Filippis S; De Giorgi S; Goracci A; La Barbera D; Mencacci C; Montagnani G; Pigato G; Vannucchi J; Vita A
    Ann Gen Psychiatry; 2022 Sep; 21(1):39. PubMed ID: 36175924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study.
    Olivares JM; González-Pinto A; Páramo M;
    Eur Psychiatry; 2021 Apr; 64(1):e40. PubMed ID: 33840396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis.
    Olivares JM; Fagiolini A
    Front Psychiatry; 2022; 13():877867. PubMed ID: 35573364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan.
    Iwata N; Inagaki A; Sano H; Niidome K; Kojima Y; Yamada S
    Adv Ther; 2020 Jul; 37(7):3324-3336. PubMed ID: 32500455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.
    Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
    Adv Ther; 2018 Oct; 35(10):1612-1625. PubMed ID: 30206822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initiation of aripiprazole once-monthly in patients with schizophrenia.
    Raoufinia A; Baker RA; Eramo A; Nylander AG; Landsberg W; Kostic D; Larsen F
    Curr Med Res Opin; 2015 Mar; 31(3):583-92. PubMed ID: 25586294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data.
    Waters HC; Stellhorn R; Touya M; Fitzgerald H; Bhattacharjee S; Citrome L
    J Med Econ; 2023; 26(1):316-325. PubMed ID: 36780296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence, Tolerability and Effective Doses of Aripiprazole Once-monthly in the Long-term Treatment of Patients with Severe Schizophrenia.
    Fernández-Miranda JJ; Díaz-Fernández S; López-Muñoz F
    Curr Pharm Des; 2021; 27(39):4078-4085. PubMed ID: 34218772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial.
    Kane JM; Schooler NR; Marcy P; Correll CU; Achtyes ED; Gibbons RD; Robinson DG
    JAMA Psychiatry; 2020 Dec; 77(12):1217-1224. PubMed ID: 32667636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in Chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study.
    Xiao L; Zhao Q; Li AN; Sun J; Wu B; Wang L; Zhang H; Zhang R; Li K; Xu X; Liu T; Zhang W; Xie S; Xu X; Tan Y; Zhang K; Zhang H; Guan N; Xian M; Uki M; Wang G
    Psychopharmacology (Berl); 2022 Jan; 239(1):243-251. PubMed ID: 34989824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study.
    Pae CU; Han C; Bahk WM; Lee SJ; Patkar AA; Masand PS
    Clin Psychopharmacol Neurosci; 2020 Feb; 18(1):153-158. PubMed ID: 31958916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.
    Naber D; Hansen K; Forray C; Baker RA; Sapin C; Beillat M; Peters-Strickland T; Nylander AG; Hertel P; Andersen HS; Eramo A; Loze JY; Potkin SG
    Schizophr Res; 2015 Oct; 168(1-2):498-504. PubMed ID: 26232241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia.
    Potkin SG; Preda A
    Expert Opin Pharmacother; 2016; 17(3):395-407. PubMed ID: 26864352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.
    Citrome L; Kamat SA; Sapin C; Baker RA; Eramo A; Ortendahl J; Gutierrez B; Hansen K; Bentley TG
    J Med Econ; 2014 Aug; 17(8):567-76. PubMed ID: 24758296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study.
    Calabrese JR; Jin N; Johnson B; Such P; Baker RA; Madera J; Hertel P; Ottinger J; Amatniek J; Kawasaki H
    Int J Bipolar Disord; 2018 Jun; 6(1):14. PubMed ID: 29886522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies.
    Kane JM; Sanchez R; Baker RA; Eramo A; Peters-Strickland T; Perry PP; Johnson BR; Tsai LF; Carson WH; McQuade RD; Fleischhacker WW
    Clin Schizophr Relat Psychoses; 2015; 9(2):79-87. PubMed ID: 25711509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study.
    Sanchez-Gistau V; Moreno MJ; Gómez-Lus S; Sicras-Mainar A; Crespo-Facorro B
    Front Psychiatry; 2023; 14():1207307. PubMed ID: 37599866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index.
    Schöttle D; Janetzky W; Luedecke D; Beck E; Correll CU; Wiedemann K
    BMC Psychiatry; 2020 Feb; 20(1):77. PubMed ID: 32087718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
    Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
    J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Noninterventional Cohort Study Assessing Time to All-Cause Treatment Discontinuation After Initiation of Aripiprazole Once Monthly or Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-Onset Schizophrenia.
    Such P; Bøg M; Kabra MS; Jørgensen KT; de Jong-Laird AC
    Prim Care Companion CNS Disord; 2021 Sep; 23(5):. PubMed ID: 34592798
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.